Veradermics, Incorporated (MANE) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MANE SEC filings page.
This page shows Veradermics, Incorporated (MANE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The figures depict a loss-making, R&D-heavy operation whose 2025 cash demands coincided with major financing inflows while liabilities exceeded assets.
In FY2025, a net loss of$70.0M and operating cash flow of-$71.6M nearly matched, showing losses translated into cash use rather than remaining mostly accounting entries. Free cash flow was-$71.6M despite only$24K of capital expenditures, so reinvestment was not the main cash drain.
R&D reached
FY2025 financing inflow of
Financial Health Signals
We do not publish a peer-relative financial health score for Veradermics, Incorporated, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Veradermics, Incorporated passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Veradermics, Incorporated reported a net loss of $70.0M while operations used $71.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Veradermics, Incorporated reported a net loss of $23.5M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Veradermics, Incorporated recorded an outflow of $14.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Veradermics, Incorporated held $319.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Veradermics, Incorporated's quarterly ROE was -2.9% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 4.1 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Veradermics, Incorporated invested $18.6M in research and development in Q2 2026. This represents an increase of 29.9% from the same quarter a year earlier. Against the prior quarter it is down 11.1%.
Veradermics, Incorporated invested $21K in capex in Q2 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
MANE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|
| R&D Expenses | $18.6M+29.9% | $20.9M+82.8% | N/A | $14.3M | $11.4M | N/A |
| SG&A Expenses | $10.9M+527.6% | $8.9M+508.8% | N/A | $1.7M | $1.5M | N/A |
| Operating Income | -$29.6Mn/m | -$29.9Mn/m | N/A | -$16.1M | -$12.9M | N/A |
| Income Tax | $0n/m | $0n/m | N/A | $0 | $0 | N/A |
| Net Income | -$23.5Mn/m | -$27.2Mn/m | N/A | -$15.6M | -$12.4M | N/A |
| EPS (Basic) | -$0.58 | -$1.32 | N/A | -$24.19 | -$19.79 | N/A |
| EPS (Diluted) | -$0.58 | -$1.32 | N/A | -$24.19 | -$19.79 | N/A |
| Diluted Shares (Avg) | 40M | 23M | N/A | 744,641 | 736,933 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense.
MANE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|
| Total Assets | $825.7M | $397.4M | $152.6M+174.8% | N/A | N/A | $55.5M |
| Current Assets | $824.7M | $397.1M | $152.5M+174.6% | N/A | N/A | $55.5M |
| Cash & Equivalents | $319.3M+3614.9% | $168.4M+419.1% | $21.8M-59.0% | $8.6M | $32.4M | $53.1M |
| Short-Term Investments | $500.6Mn/m | $222.4Mn/m | $120.1Mn/m | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Total Liabilities | $12.1M | $6.7M | $273.6M+163.1% | N/A | N/A | $104.0M |
| Current Liabilities | $11.7M | $6.7M | $9.2M+94.0% | N/A | N/A | $4.7M |
| Non-Current Liabilities | $428K | $0 | $264.5M+166.4% | N/A | N/A | $99.3M |
| Total Equity | $813.6Mn/m | $390.6Mn/m | -$121.0Mn/m | -$76.1M | -$60.7M | -$48.5M |
| Retained Earnings | -$174.2M | -$150.7M | -$123.4Mn/m | N/A | N/A | -$49.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
MANE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.5Mn/m | -$21.2Mn/m | N/A | -$15.6M | -$13.3M | N/A |
| Stock-Based Compensation | $3.5M+2957.4% | $5.3M+2369.0% | N/A | $115K | $213K | N/A |
| Capital Expenditures | $21Kn/m | $0-100.0% | N/A | $0 | $19K | N/A |
| Free Cash Flow | -$14.5Mn/m | -$21.2Mn/m | N/A | -$15.6M | -$13.3M | N/A |
| Investing Cash Flow | -$277.3Mn/m | -$101.3Mn/m | N/A | -$8.3M | -$15.8M | N/A |
| Financing Cash Flow | $442.7M+343076.7% | $269.1M+3095.0% | N/A | $129K | $8.4M | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.
MANE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$121.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Veradermics, Incorporated MANE | FY2025 | N/A | -$70.0M | N/A | $5.4B | — |
| Oruka Therapeutics, Inc. ORKA | FY2025 | N/A | -$105.4M | N/A | $6.3B | — |
| CG Oncology, Inc. CGON | FY2025 | $4.0M | -$161.0M | N/A | $5.5B | 61/100 |
| Scholar Rock Holding Corporation SRRK | FY2025 | $0 | -$377.9M | N/A | $5.2B | — |
| Ligand Pharmaceuticals Inc. LGND | FY2025 | $268.1M | $124.5M | 46.4% | $6.1B | 70/100 |
| Kodiak Sciences Inc KOD | FY2025 | N/A | -$230.0M | N/A | $6.1B | — |
Where Veradermics, Incorporated Ranks
Frequently Asked Questions
No, Veradermics, Incorporated (MANE) reported a net loss of $70.0M in fiscal year 2025.
Veradermics, Incorporated (MANE) recorded an outflow of $71.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Veradermics, Incorporated (MANE) recorded an outflow of $71.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Veradermics, Incorporated (MANE) had $152.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Veradermics, Incorporated (MANE) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Veradermics, Incorporated (MANE) invested $62.1M in research and development during fiscal year 2025.
Veradermics, Incorporated (MANE) had a current ratio of 16.66 as of fiscal year 2025, which is generally considered healthy.
Veradermics, Incorporated (MANE) had a return on assets of -45.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Veradermics, Incorporated (MANE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.4B as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Veradermics, Incorporated (MANE) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $5.4B as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Veradermics, Incorporated (MANE) held $141.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $71.6M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Veradermics, Incorporated (MANE) has negative shareholder equity of -$121.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Veradermics, Incorporated (MANE) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Veradermics, Incorporated (MANE) reported a net loss of $70.0M while operations used $71.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.